Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Sebacoyl Dinalbuphine Ester vs Bain in Healthy Volunteers
NCT02446301Phase 1Completed
- Sponsor
- Lumosa Therapeutics
- Start
- Jan 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dinalbuphine sebacate in pain, sponsored by Lumosa Therapeutics. Primary endpoint: Blood concentration of Nalbuphine HCl at 336 hours. Started Jan 2015; status: completed.
02
Drugs
dinalbuphine sebacate
03
Conditions
pain
Beyond the preview
Go deeper on NCT02446301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446301.